(Q36303846)

13 August 2017

1 reference

title

Targeting angiogenesis in cancer: clinical development of bevacizumab (English)

1 reference

13 August 2017

1 reference

David J Kerr

1

1 reference

13 August 2017

publication date

1 November 2004

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

1

1 reference

13 August 2017

issue

1

1 reference

13 August 2017

page(s)

39-43

1 reference

VEGF and the quest for tumour angiogenesis factors

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Bevacizumab in the treatment of breast cancer: rationale and current data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

Transplacental carcinogenesis by stilbestrol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

inferred from DOI database lookup

7 January 2021

based on heuristic

Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0026

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NCPONC0026

1 reference

13 August 2017

1 reference